In-hospital mortality in SARS-CoV-2 stratified by the use of corticosteroid

Naser Alotaibi; Moudhi Alroomi; Wael Aboelhassan; Soumoud  Hussein; Rajesh Rajan; Noor  AlNasrallah; Mohammad  Al Saleh; Maryam Ramadhan; Kobalava D.  Zhanna; Jiazhu Pan; Haya Malhas; Hassan Abdelnaby; Farah  Almutairi; Bader  Al-Bader; Ahmad Alsaber; Mohammed Abdullah

doi:10.1016/j.amsu.2022.104105

In-hospital mortality in SARS-CoV-2 stratified by the use of corticosteroid

Naser Alotaibi, Moudhi Alroomi, Wael Aboelhassan, Soumoud Hussein, Rajesh Rajan, Noor AlNasrallah, Mohammad Al Saleh, Maryam Ramadhan, Kobalava D. Zhanna, Jiazhu Pan, Haya Malhas, Hassan Abdelnaby, Farah Almutairi, Bader Al-Bader, Ahmad Alsaber, Mohammed Abdullah

Mathematics And Statistics

Research output: Contribution to journal › Article › peer-review

3 Downloads (Pure)

Abstract

Objective: To investigate COVID-19 related mоrtаlity according to the use of corticosteroid therapy. Design: Retrospective cohort study. Setting: Two tertiary hospitals in Kuwait. Participants: Overall, 962 patients with confirmed SARS-CoV-2 infection, were stratified according to whether they were treated with corticosteroids (dexamethasone or methylprednisolone). The mean age of the patients was 50.2 ± 15.9 years and 344/962 (35.9%) were female. Main outcome measures: In-hospital mortality and cumulative all-cause mortality. Results: Compared to non-corticosteroid therapy patients, corticosteroid therapy patients had a higher prevalence of hypertension, diabetes mellitus, cardiovascular disease, chronic lung disease, and chronic kidney disease; a longer hospital stay (median [IQR]: 17.0 [5.0–57.3] days vs 14.0 [2.0–50.2] days); and a higher in-hospital mortality (51/199 [25.6%] vs 36/763 [4.7%]). Logistic regression analysis showed a higher in-hospital mortality in the corticosteroid group (adjusted odds ratio [aOR]: 4.57, 95% confidence interval [CI]: 2.64–8.02, p < 0.001). Cox proportional hazards regression showed that corticosteroid use was a significant predictor of mortality (hazard ratio [HR]: 3.96, p < 0.001). Conclusions: In-hospital mortality in patients with SARS-CoV-2 on corticosteroid therapy was 4.6 times higher than in those without corticosteroid therapy.

Original language	English
Article number	104105
Journal	Annals of Medicine and Surgery
Volume	80
Early online date	29 Jun 2022
DOIs	https://doi.org/10.1016/j.amsu.2022.104105
Publication status	Published - Aug 2022

Keywords

corticosteroids
SARS-COV-2
in-hospital mortality
COVID-19
age

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.amsu.2022.104105Licence: CC BY-NC-ND 4.0

Alotaibi-etal-AMS-2022-In-hospital-mortality-in-SARS-CoV-2-stratifiedFinal published version, 1.05 MBLicence: CC BY-NC-ND 4.0

Cite this

Alotaibi, N., Alroomi, M., Aboelhassan, W., Hussein, S., Rajan, R., AlNasrallah, N., Al Saleh, M., Ramadhan, M., Zhanna, K. D., Pan, J., Malhas, H., Abdelnaby, H., Almutairi, F., Al-Bader, B., Alsaber, A., & Abdullah, M. (2022). In-hospital mortality in SARS-CoV-2 stratified by the use of corticosteroid. Annals of Medicine and Surgery, 80, [104105]. https://doi.org/10.1016/j.amsu.2022.104105

@article{a3122ae494e641b0904cbc69be979892,

title = "In-hospital mortality in SARS-CoV-2 stratified by the use of corticosteroid",

abstract = "Objective: To investigate COVID-19 related mоrtаlity according to the use of corticosteroid therapy. Design: Retrospective cohort study. Setting: Two tertiary hospitals in Kuwait. Participants: Overall, 962 patients with confirmed SARS-CoV-2 infection, were stratified according to whether they were treated with corticosteroids (dexamethasone or methylprednisolone). The mean age of the patients was 50.2 ± 15.9 years and 344/962 (35.9%) were female. Main outcome measures: In-hospital mortality and cumulative all-cause mortality. Results: Compared to non-corticosteroid therapy patients, corticosteroid therapy patients had a higher prevalence of hypertension, diabetes mellitus, cardiovascular disease, chronic lung disease, and chronic kidney disease; a longer hospital stay (median [IQR]: 17.0 [5.0–57.3] days vs 14.0 [2.0–50.2] days); and a higher in-hospital mortality (51/199 [25.6%] vs 36/763 [4.7%]). Logistic regression analysis showed a higher in-hospital mortality in the corticosteroid group (adjusted odds ratio [aOR]: 4.57, 95% confidence interval [CI]: 2.64–8.02, p < 0.001). Cox proportional hazards regression showed that corticosteroid use was a significant predictor of mortality (hazard ratio [HR]: 3.96, p < 0.001). Conclusions: In-hospital mortality in patients with SARS-CoV-2 on corticosteroid therapy was 4.6 times higher than in those without corticosteroid therapy.",

keywords = "corticosteroids, SARS-COV-2, in-hospital mortality, COVID-19, age",

author = "Naser Alotaibi and Moudhi Alroomi and Wael Aboelhassan and Soumoud Hussein and Rajesh Rajan and Noor AlNasrallah and {Al Saleh}, Mohammad and Maryam Ramadhan and Zhanna, {Kobalava D.} and Jiazhu Pan and Haya Malhas and Hassan Abdelnaby and Farah Almutairi and Bader Al-Bader and Ahmad Alsaber and Mohammed Abdullah",

year = "2022",

month = aug,

doi = "10.1016/j.amsu.2022.104105",

language = "English",

volume = "80",

}

Alotaibi, N, Alroomi, M, Aboelhassan, W, Hussein, S, Rajan, R, AlNasrallah, N, Al Saleh, M, Ramadhan, M, Zhanna, KD, Pan, J, Malhas, H, Abdelnaby, H, Almutairi, F, Al-Bader, B, Alsaber, A & Abdullah, M 2022, 'In-hospital mortality in SARS-CoV-2 stratified by the use of corticosteroid', Annals of Medicine and Surgery, vol. 80, 104105. https://doi.org/10.1016/j.amsu.2022.104105

TY - JOUR

T1 - In-hospital mortality in SARS-CoV-2 stratified by the use of corticosteroid

AU - Alotaibi, Naser

AU - Alroomi, Moudhi

AU - Aboelhassan, Wael

AU - Hussein, Soumoud

AU - Rajan, Rajesh

AU - AlNasrallah, Noor

AU - Al Saleh, Mohammad

AU - Ramadhan, Maryam

AU - Zhanna, Kobalava D.

AU - Pan, Jiazhu

AU - Malhas, Haya

AU - Abdelnaby, Hassan

AU - Almutairi, Farah

AU - Al-Bader, Bader

AU - Alsaber, Ahmad

AU - Abdullah, Mohammed

PY - 2022/8

Y1 - 2022/8

N2 - Objective: To investigate COVID-19 related mоrtаlity according to the use of corticosteroid therapy. Design: Retrospective cohort study. Setting: Two tertiary hospitals in Kuwait. Participants: Overall, 962 patients with confirmed SARS-CoV-2 infection, were stratified according to whether they were treated with corticosteroids (dexamethasone or methylprednisolone). The mean age of the patients was 50.2 ± 15.9 years and 344/962 (35.9%) were female. Main outcome measures: In-hospital mortality and cumulative all-cause mortality. Results: Compared to non-corticosteroid therapy patients, corticosteroid therapy patients had a higher prevalence of hypertension, diabetes mellitus, cardiovascular disease, chronic lung disease, and chronic kidney disease; a longer hospital stay (median [IQR]: 17.0 [5.0–57.3] days vs 14.0 [2.0–50.2] days); and a higher in-hospital mortality (51/199 [25.6%] vs 36/763 [4.7%]). Logistic regression analysis showed a higher in-hospital mortality in the corticosteroid group (adjusted odds ratio [aOR]: 4.57, 95% confidence interval [CI]: 2.64–8.02, p < 0.001). Cox proportional hazards regression showed that corticosteroid use was a significant predictor of mortality (hazard ratio [HR]: 3.96, p < 0.001). Conclusions: In-hospital mortality in patients with SARS-CoV-2 on corticosteroid therapy was 4.6 times higher than in those without corticosteroid therapy.

AB - Objective: To investigate COVID-19 related mоrtаlity according to the use of corticosteroid therapy. Design: Retrospective cohort study. Setting: Two tertiary hospitals in Kuwait. Participants: Overall, 962 patients with confirmed SARS-CoV-2 infection, were stratified according to whether they were treated with corticosteroids (dexamethasone or methylprednisolone). The mean age of the patients was 50.2 ± 15.9 years and 344/962 (35.9%) were female. Main outcome measures: In-hospital mortality and cumulative all-cause mortality. Results: Compared to non-corticosteroid therapy patients, corticosteroid therapy patients had a higher prevalence of hypertension, diabetes mellitus, cardiovascular disease, chronic lung disease, and chronic kidney disease; a longer hospital stay (median [IQR]: 17.0 [5.0–57.3] days vs 14.0 [2.0–50.2] days); and a higher in-hospital mortality (51/199 [25.6%] vs 36/763 [4.7%]). Logistic regression analysis showed a higher in-hospital mortality in the corticosteroid group (adjusted odds ratio [aOR]: 4.57, 95% confidence interval [CI]: 2.64–8.02, p < 0.001). Cox proportional hazards regression showed that corticosteroid use was a significant predictor of mortality (hazard ratio [HR]: 3.96, p < 0.001). Conclusions: In-hospital mortality in patients with SARS-CoV-2 on corticosteroid therapy was 4.6 times higher than in those without corticosteroid therapy.

KW - corticosteroids

KW - SARS-COV-2

KW - in-hospital mortality

KW - COVID-19

KW - age

U2 - 10.1016/j.amsu.2022.104105

DO - 10.1016/j.amsu.2022.104105

M3 - Article

VL - 80

M1 - 104105

ER -

In-hospital mortality in SARS-CoV-2 stratified by the use of corticosteroid

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this